Cellectar Biosciences, Inc. (CLRB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Cellectar Biosciences reported revenue of $0. Net income was -$21.8M, or -$8.35 per diluted share. Operating activities generated -$23.1M of cash, leaving -$23.1M of free cash flow. At fiscal year end, Cellectar Biosciences held $15.0M in total assets against $5.1M in total liabilities, including $13.2M of cash and equivalents.
Open the full interactive Cellectar Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Cellectar Biosciences Key Stats
| Share Price | $1.39 |
|---|---|
| Market Cap | $17.0M |
| 52-Week Range | $1.39 – $4.98 |
| Shares Outstanding | 12.2 million (basic, 2026 Q2) |
Cellectar Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$15.3M | -$24.1M | -$28.8M | -$39.0M | -$51.8M | -$23.0M |
| Pre-Tax Income | -$15.1M | -$24.1M | -$28.7M | -$38.0M | -$44.5M | -$21.8M |
| Income Tax | — | — | -$60,000 | -$60,000 | $66,000 | — |
| Net Income | -$15.1M | -$24.1M | -$28.6M | -$38.0M | -$44.6M | -$21.8M |
| Diluted EPS | -$228.00 | -$228.00 | -$121.50 | -$93.30 | -$42.00 | -$8.35 |
Cellectar Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.4M | -$5.3M | -$5.7M | -$6.9M |
| Diluted EPS | -$1.41 | -$2.03 | -$1.33 | -$0.57 |
Cellectar Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $57.2M | $35.7M | $19.9M | $9.6M | $23.3M | $13.2M |
| Current Assets | $57.9M | $36.6M | $20.5M | $10.5M | $24.3M | $14.0M |
| Total Assets | $58.7M | $37.2M | $21.6M | $12.1M | $25.5M | $15.0M |
| Current Liabilities | $3.6M | $4.0M | $5.5M | $12.9M | $9.4M | $4.7M |
| Total Liabilities | $3.9M | $4.2M | $6.1M | $13.4M | $9.8M | $5.1M |
| Shareholders' Equity | $54.8M | $33.0M | $15.5M | -$1.4M | $14.3M | $8.5M |
Cellectar Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$13.9M | -$22.6M | -$25.2M | -$32.4M | -$47.6M | -$23.1M |
| Cash From Investing | -$62,353 | -$141,361 | -$225,971 | -$864,038 | -$104,195 | -$5,880 |
| Cash From Financing | $60.5M | $1.2M | $9.6M | $22.9M | $61.4M | $13.0M |
| Free Cash Flow | -$14.0M | -$22.7M | -$25.4M | -$33.2M | -$47.7M | -$23.1M |
Figures from Cellectar Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cellectar Biosciences financials page for every line item.
Cellectar Biosciences Company Profile
| Ticker | CLRB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Florham Park, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001279704 |
Frequently Asked Questions
What was Cellectar Biosciences' revenue in fiscal 2025?
Cellectar Biosciences (CLRB) reported revenue of $0 for fiscal 2025.
What is Cellectar Biosciences' annual revenue history?
Cellectar Biosciences' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Cellectar Biosciences' net income in fiscal 2025?
Cellectar Biosciences reported net income of -$21.8M for fiscal 2025.
What was Cellectar Biosciences' earnings per share (EPS) in fiscal 2025?
Cellectar Biosciences' diluted EPS was -$8.35 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cellectar Biosciences generate in fiscal 2025?
Cellectar Biosciences generated -$23.1M of free cash flow in fiscal 2025.
What was Cellectar Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cellectar Biosciences reported revenue of $0.
How many shares of Cellectar Biosciences are outstanding?
Cellectar Biosciences reported a weighted average of 12.2 million basic shares outstanding in 2026 Q2.
What is Cellectar Biosciences' market cap?
Based on its latest closing price, Cellectar Biosciences (CLRB) has a market capitalization of about $17.0M.
When does Cellectar Biosciences' fiscal year end?
Cellectar Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Cellectar Biosciences headquartered?
Cellectar Biosciences lists its business address in Florham Park, New Jersey in its SEC filings.